Sarcopenia in Children

Sarcopenia Clinical Trial

Official title:

Sarcopenia; a New Issue in Juvenile Idiopathic Arthritis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05291416
• Other study ID #: pediatric rheumatology Kassab
• Status: Not yet recruiting
• Start date: April 1, 2022
• Est. completion date: December 31, 2022

Study information

• Verified date: March 2022
• Source: University Tunis El Manar
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Juvenile idiopathic arthritis (AJI), is a frequent inflammatory disease in children, characterized by pain, arthritis, and deformities. Chronic inflammation leads to physical inactivity and can be associated with muscle weakness around affected joints, low bone strength, and mass(3). To our knowledge, no study has focused on the prevalence of sarcopenia in JIA and the data on the muscle disorder are lacking. The purpose of the present study is to detect sarcopenia and identify associated factors in children with JIA

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: December 31, 2022
• Est. primary completion date: October 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 4 Years to 16 Years

Eligibility

Inclusion Criteria:

• children with juvenile idiopathic arthritis fulfilling the ILAR criteria

Exclusion Criteria:

• We excluded patients who have a prosthesis, nutritional problems, inflammatory bowel disease, coeliac disease, temporomandibular involvement, or another chronic disease.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Juvenile
• Juvenile Idiopathic Arthritis
• Sarcopenia

Intervention

Diagnostic Test:
• densitometry/ handgrip dynamometer
all patients will undergo the Dual-energy X-ray absorptiometry (DXA) and the muscle strength assessment using the handgrip dynamometer

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Tunis El Manar

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	skeletal muscle mass	Dual-energy X-ray absorptiometry (DXA) measures the appendicular lean mass ( the sum of the lean mass of the arms and legs) and adjusted to the body mass index	4 months
Secondary	muscle strenght	Three consecutive trials will be measured by the handgrip dynamometer between the dominant and non-dominant sides. the highest value will be used and adjusted to the body mass index	5 months